Lidocaine Patch and Menthol

Manufacturer
Florrax Pharmaceutical | Amneal Pharmaceuticals, LLC | Florrax Pharmaceutical Corp.
Effective date
2026-03-25
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 22:11:59

Label at a glance#

ProductOrvex
Active ingredientLIDOCAINE, menthol
Label structure24 sections

Dosage and administration

Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24 hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner (see HANDLING AND DISPOSAL ). Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patie...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Lidocaine Patch 5% & Menthol Roll-on Gel
Rx Only

DESCRIPTION

DESCRIPTION SECTION

Lidocaine patch 5% is comprised of an adhesive material containing 5% lidocaine, USP, which is applied to a non-woven polyester backing and covered with a polyethylene terephthalate (PET) film release liner. The release liner is removed prior to application to the skin. The size of the patch is 10 cm × 14 cm.

Lidocaine, USP is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl), has an octanol: water partition ratio of 43 at pH 7.4, and has the following structure:

chemical structure
chemical structure

Each adhesive patch contains 700 mg of lidocaine, USP (50 mg per gram adhesive) in an aqueous base. It also contains the following inactive ingredients: dihydroxyaluminum aminoacetate, disodium edetate, gelatin, glycerin, kaolin, methylparaben, polyvinyl alcohol, propylparaben, propylene glycol, sodium carboxymethylcellulose, partially neutralized sodium polyacrylate, D-sorbitol, tartaric acid, and urea.

CLINICAL STUDIES

CLINICAL STUDIES SECTION

Single-dose treatment with lidocaine patch 5% was compared to treatment with vehicle patch (without lidocaine), and to no treatment (observation only) in a double-blind, crossover clinical trial with 35 post-herpetic neuralgia patients. Pain intensity and pain relief scores were evaluated periodically for 12 hours. Lidocaine patch 5% performed statistically better than vehicle patch in terms of pain intensity from 4 to 12 hours.

Multiple-dose, two-week treatment with lidocaine patch 5% was compared to vehicle patch (without lidocaine) in a double-blind, crossover clinical trial of withdrawal-type design conducted in 32 patients, who were considered as responders to the open-label use of lidocaine patch 5% prior to the study. The constant type of pain was evaluated but not the pain induced by sensory stimuli (dysesthesia). Statistically significant differences favoring lidocaine patch 5% were observed in terms of time to exit from the trial (14 versus 3.8 days at p-value <0.001), daily average pain relief, and patient's preference of treatment. About half of the patients also took oral medication commonly used in the treatment of post-herpetic neuralgia. The extent of use of concomitant medication was similar in the two treatment groups.

INDICATION AND USAGE

INDICATIONS & USAGE SECTION

Lidocaine patch 5% is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Lidocaine patch 5% is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

WARNINGS

WARNINGS SECTION

Risk of Methemoglobinemia

Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e. oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

Accidental Exposure in Children

Even a used lidocaine patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or a pet to suffer serious adverse effects from chewing or ingesting a new or used lidocaine patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of lidocaine patch 5% out of the reach of children, pets and others (see HANDLING AND DISPOSAL).

Excessive Dosing

Excessive dosing by applying lidocaine patch 5% to larger areas or for longer than the recommended wearing time could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects (see ADVERSE REACTIONS, Systemic Reactions). Lidocaine toxicity could be expected at lidocaine blood concentrations above 5 mcg/mL. The blood concentration of lidocaine is determined by the rate of systemic absorption and elimination. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increasing the blood concentration of lidocaine. With recommended dosing of lidocaine patch 5%, the average peak blood concentration is about 0.13 mcg/mL, but concentrations higher than 0.25 mcg/mL have been observed in some individuals.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Application Site Reactions During or immediately after treatment with lidocaine patch 5%, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.

Allergic Reactions Allergic and anaphylactoid reactions associated with lidocaine, although rare, can occur. They are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

Other Adverse Events Due to the nature and limitation of spontaneous reports in postmarketing surveillance, causality has not been established for additional reported adverse events including:

Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor.

Systemic (Dose-Related) Reactions Systemic adverse reactions following appropriate use of lidocaine patch 5% are unlikely, due to the small dose absorbed (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Systemic adverse effects of lidocaine are similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light-headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.

OVERDOSAGE

OVERDOSAGE SECTION

Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose (see ADVERSE REACTIONS, Systemic Reactions), drug blood concentration should be checked. The management of overdose includes close monitoring, supportive care, and symptomatic treatment. Dialysis is of negligible value in the treatment of acute overdose with lidocaine.

In the absence of massive topical overdose or oral ingestion, evaluation of symptoms of toxicity should include consideration of other etiologies for the clinical effects, or overdosage from other sources of lidocaine or other local anesthetics.

The oral LD50 of lidocaine HCl is 459 (346 to 773) mg/kg (as the salt) in non-fasted female rats and 214 (159 to 324) mg/kg (as the salt) in fasted female rats, which are equivalent to roughly 4000 mg and 2000 mg, respectively, in a 60 kg to 70 kg man based on the equivalent surface area dosage conversion factors between species.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply lidocaine patch 5% to intact skin to cover the most painful area. Apply the prescribed number of patches (maximum of 3), only once for up to 12 hours within a 24 hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner (see HANDLING AND DISPOSAL). Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.

If irritation or a burning sensation occurs during application, remove the patch(es) and do not reapply until the irritation subsides.

When lidocaine patch 5% is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.

Lidocaine patch 5% may not stick if it gets wet. Avoid contact with water, such as bathing, swimming or showering.

HANDLING AND DISPOSAL

SPL UNCLASSIFIED SECTION

Hands should be washed after the handling of lidocaine patch 5%, and eye contact with lidocaine patch 5% should be avoided. Do not store patch outside the sealed envelope. Apply immediately after removal from the protective envelope. Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them. Lidocaine patch 5% should be kept out of the reach of children.

HOW SUPPLIED

HOW SUPPLIED SECTION

Lidocaine patch 5% is available as the following:

Carton of 30 patches, packaged into individual child-resistant envelopes.

NDC 65162-791-08

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

For more information, call Amneal Pharmaceuticals at 1-877-835-5472.

Distributed by:

Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

Rev. 10-2020-03

PRINCIPAL DISPLAY PANEL

SPL UNCLASSIFIED SECTION

pouch front
pouch front

SPL UNCLASSIFIED SECTION

gh
gh

SPL UNCLASSIFIED SECTION

carton
carton

OTC - ACTIVE INGREDIENT SECTION

HealthWise Roll-on Menthol Pain Relief Gel

HealthWise Rol-on Menthol Pain Relief Gel

Active Ingredient

Menthol 6%

OTC - WHEN USING SECTION

When using this product avoid contacts with the eyes or mucous membranes. do not apply to wounds or damaged skin. do not apply to irritated skin. do not bandage. wash hands after use with cool water. do not use with heating pad or device.

OTC - PURPOSE SECTION

Menthol 6%------------------------------------------------------------Topical Analgesic

WARNINGS SECTION

For external use only.

OTC - STOP USE SECTION

Stop use and ask a doctor if condition worsens redness is present irritation develops symptoms persist for more than 7 days or clear up and occur again within a few days you experience signs of skin injury, such as pain, sweling, or blistering where the product was applied

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

keep out of reach of children if swallowed,get medical help or contact a poson Control Center Immediately.

INACTIVE INGREDIENT SECTION

Inactive ingredients alcohol, aloe barbadensis leaf juice, aminomethyl propanol, arctium lappa extract, arnica montana flower extract, camelia sinensis leaf extract, camphor, carbomer, chamomila recutita (matricaria) flower water, glycerin, ilex paraguariensis leaf extract, isopropyl myristate, maltodextrin, water

DOSAGE & ADMINISTRATION SECTION

Direction: Apply to affectered area not more that 3 to 4 times daily.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdppdppdppdp

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

The packaging for Orvex is shown below.

pdp
pdp

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1745091lidocaine 5 % Medicated PatchPSN4
415976menthol 6 % Topical GelPSN4
1745091lidocaine 0.05 MG/MG Medicated PatchSCD4
415976menthol 0.06 MG/MG Topical GelSCD4
1745091lidocaine 5 % Medicated PatchSY4
415976menthol 6 % Topical GelSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LIDOCAINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130365162791044GTIN-13: 0365162791044
EAN-13: 0365162791044
GTIN-12: 365162791044
UPC-A: 365162791044
GTIN storage (14 digits): 00365162791044
orvex-kit-3.jpg
BarcodeEAN-130365162791082GTIN-13: 0365162791082
EAN-13: 0365162791082
GTIN-12: 365162791082
UPC-A: 365162791082
GTIN storage (14 digits): 00365162791082
orvex-kit-4.jpg
Data codeCode 128700104orvex-kit-4.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
070fbed5-7088-434a-a7ce-f2a64d8d40acProduct name220260107
bee66ce1-adb7-9d3b-67d9-582e4c54e80fProduct name520250819
860a93dc-4863-49cc-b284-6bbe8191bc48Product name420250214
eaba870a-6a9d-442e-8643-87b3f558a451Product name120250117
9b4cf230-fd05-41d5-98c6-5db9ecb27b86Product name120230117
7d755fa1-1087-4dcd-98f0-6d4bba479a57Product name320210602
f52be47f-7aa7-46c0-b1fa-50c18dd50206Product name120201029
aed701d5-9c75-dfaf-7154-cde46179faeaProduct name920200313
fa8b5901-e681-426f-82fe-54f6d81ec698Product name420180619
332d03e4-aa24-4b11-841a-02bf41081920Product name120171221
c08ab52f-2fc8-4409-9d9f-ed8edc0bd070Product name120171221
68ed98f8-24c2-44a0-944a-6d36e82ce25aProduct name120141222
1cd42bc2-a430-c72b-636d-991b235fbf80Product name120140508
49fa150c-f0de-cce7-3d9c-993ed81c5698Product name120140508
4d7ae718-ed00-bae8-2abe-9eaec1eef7ffProduct name120140508
9137811f-f279-8640-5aeb-99fa2145d64dProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
65162-791-08Orvex1 in 1 POUCHPATCH30700 mg4
65162-791-08Orvex30 in 1 CARTONPATCH700 mg4
72667-073-01Orvex89 g in 1 BOTTLE, PLASTICGEL89 g6 g in 100g4
84460-802-01Orvex1 in 1 KITKIT14

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
84460-802-01EA - Each84460-802f33dc58b-821b-4bb1-8b8e-031b5d62c7f612026-05-22

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 32 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
65162-79165162-791-08
84460-80284460-802-01
72667-07372667-073-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 30 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
32026-03-25legacy-cache2026-10-21 11:47:54

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A206463-001LIDOCAINELIDOCAINE5%PATCH / TOPICALAB2020-08-24

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A206463-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 41 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24d4dbc9d85df4…
2026-10-15 13:18:302026-09A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24c2088c7a36db…
2026-09-14 22:38:342026-08A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-2484e616aacf4f…
2026-08-18 06:07:402026-07A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-2431067a03dcf5…
2025-08-23 18:47 UTC2025-08A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-246a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-2403ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-242680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-245bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-2479d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-241e350fbaab3a…
2024-05-31 18:47 UTC2024-05A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-248072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-245c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-245d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-244b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-2487673890dc5c…
2021-03-12 10:30 UTC2021-03A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-245aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-248869cabd3fbd…
2020-11-12 02:37 UTC2020-11A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-246a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-241c564ffb4f44…
2023-12-20 04:57 UTC2023-12A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-249b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-243f0d92c62455…
2023-05-13 08:27 UTC2023-05A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24053a50430f4f…
2023-01-26 05:58 UTC2023-01A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-243bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-243a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A206463-001LIDOCAINE5%PATCH / TOPICALAB2020-08-24cb3db0bc1861…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 41 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A206463-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A206463-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A206463-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A206463-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A206463-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A206463-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A206463-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A206463-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A206463-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A206463-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A206463-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A206463-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A206463-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A206463-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A206463-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A206463-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A206463-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A206463-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A206463-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A206463-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A206463-001AB14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A206463-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A206463-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A206463-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A206463-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A206463-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A206463-001AB1c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A206463-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A206463-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A206463-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A206463-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A206463-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A206463-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A206463-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A206463-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A206463-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A206463-001AB13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A206463-001AB1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A206463-001AB1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A206463-001AB1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 8 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OrvexaLIDOCAINE AND MENTHOLFlorrax Pharmaceutical6760e4cf-475a-4f3e-a700-3f30221daffb2026-09-25Warnings, Adverse reactionsExact identifier
ndc (package): 72667-073-01
ndc (package): 65162-791-08
ndc11 (package): 72667007301
ndc11 (package): 65162079108
Relivyx PlusLIDOCAINEV2 Pharma LLC08aeb3f5-56ea-4fd7-b151-e6dc65f202da2026-04-16Warnings, Adverse reactionsExact identifier
ndc (package): 72667-073-01
ndc11 (package): 72667007301
OrvexLIDOCAINE AND MENTHOLFlorrax Pharmaceutical3dd9a87e-9860-461a-b9ce-042942de839f2026-03-25Warnings, Adverse reactionsExact identifier
ndc (package): 84460-802-01
ndc (package): 72667-073-01
ndc (package): 65162-791-08
ndc (product): 84460-802
ndc11 (package): 84460080201
ndc11 (package): 72667007301
ndc11 (package): 65162079108
spl id: 673164b0-0ed4-4e3f-881c-861abbd63df1
spl set id: 3dd9a87e-9860-461a-b9ce-042942de839f
MyDerm Pro Freeze Cooling Menthol Pain Relief Roll-OnMENTHOLInspec Solutions12ff9b9a-73e5-ce31-e063-6294a90aeaf82026-01-09WarningsExact identifier
ndc (package): 72667-073-01
ndc (product): 72667-073
ndc11 (package): 72667007301
Syntherma PlusLIDOCAINEV2 Pharma, LLC1a312322-9c4a-4f14-be7f-05ccad1601bf2025-07-01Warnings, Adverse reactionsExact identifier
ndc (package): 72667-073-01
ndc (package): 65162-791-08
ndc11 (package): 72667007301
ndc11 (package): 65162079108
Elemar PatchLIDOCAINEV2 Pharma, LLC3de6bb95-3673-45c4-bf11-90ec858c37d92025-06-20Warnings, Adverse reactionsExact identifier
ndc (package): 72667-073-01
ndc (package): 65162-791-08
ndc11 (package): 72667007301
ndc11 (package): 65162079108
LMR PlusLIDOCAINEV2 Pharma, LLC7c84e443-67fe-40b5-b721-86e9e7c4d4902024-12-30Warnings, Adverse reactionsExact identifier
ndc (package): 72667-073-01
ndc (package): 65162-791-08
ndc11 (package): 72667007301
ndc11 (package): 65162079108
LidocaineLIDOCAINEAmneal Pharmaceuticals LLC1f46bdfd-3a38-49a3-a505-0192790486d02024-10-28Warnings, Adverse reactionsExact identifier
ndc (package): 65162-791-08
ndc (product): 65162-791
ndc11 (package): 65162079108

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.